CJC-1295 / Ipamorelin

What is CJC-1295 + Ipamorelin?

CJC-1295 and Ipamorelin are two experimental peptides that stimulate the body's own growth-hormone release through different receptors: CJC-1295 mimics the body's natural growth-hormone-releasing hormone (GHRH), while Ipamorelin activates the ghrelin receptor-together producing natural, pulse-like HGH surges rather than replacing the hormone directly.

Neither substance is the hormone itself. Instead, both act as growth-hormone secretagogues-chemical messengers that signal the pituitary gland (the small hormone-control gland at the base of the brain) to release more of the body's own growth hormone. This distinction matters: injecting exogenous (external) HGH suppresses the body's natural production, whereas secretagogues are designed to amplify existing release patterns.

Both substances appear on the WADA Prohibited List and are banned in competitive sports as well as under military regulations. Athletes and military personnel risk direct suspensions and professional consequences.

Critical: two completely different variants of CJC-1295

Anyone encountering "CJC-1295" must understand that two fundamentally different versions exist, and confusing them carries significant safety implications:

• With DAC (Drug Affinity Complex): A molecular anchor extends the half-life to 6-8 days, producing a sustained, continuous release. The clinical development of this variant by the company ConjuChem was halted after a study participant died during a Phase II trial from an apparent cardiovascular event. ConjuChem subsequently filed for bankruptcy. The exact circumstances and causality were not fully detailed in the literature.
• Without DAC (also called Modified GRF 1-29): A shorter half-life that supports a pulsatile release pattern intended to mimic the body's natural GH secretion pulses. This is the variant typically discussed in community and anti-aging contexts.

Buyers frequently see only "CJC-1295" on a label or listing and may not know which variant they hold. Given the safety history of the DAC version, this is an essential distinction that must be verified before any use.

How does CJC-1295 + Ipamorelin work?

The two peptides act on two different receptor systems that converge on growth-hormone release: CJC-1295 binds the GHRH receptor (triggering the cAMP signaling pathway - an internal cell message that amplifies the GH release signal) to extend and amplify GH pulses, while Ipamorelin binds the ghrelin receptor GHS-R1a (triggering a rapid calcium-mediated GH spike via a different internal cell messaging route), and together they produce a combined pulse larger than either alone.

The rationale for combining these two peptides lies in their complementary mechanisms, each targeting a separate "docking site" on pituitary cells:

• CJC-1295 (GHRH receptor): Binds as an analog of growth-hormone-releasing hormone to the GHRH receptor, activating the Gs/cAMP signaling pathway. This increases both pulsatile GH secretion and IGF-1 (Insulin-like Growth Factor 1, the substance through which HGH exerts most of its effects) levels.
• Ipamorelin (Ghrelin receptor GHS-R1a): A pentapeptide that selectively activates the ghrelin receptor via the Gq/calcium signaling pathway, producing a rapid GH peak approximately 0.67 hours after administration, followed by an exponential decline. Unlike less selective compounds, it has minimal impact on prolactin (a hormone involved in milk production) and ACTH (the adrenal stress hormone), as well as on cortisol.
• Synergy mechanism: Activating both receptors simultaneously generates a GH pulse larger than the sum of individual effects, primarily through convergent intracellular signaling pathways (cAMP + calcium) at the somatotrophs. The community claim that CJC-1295 directly increases ghrelin-receptor synthesis and thereby prevents the downregulation that would occur with Ipamorelin alone is frequently cited but is not supported by published pharmacology; it appears to be an extrapolation from the 54-fold synergy data (GHRP-2, animal/in vitro) to this specific stack.

The "54-fold synergy" myth

Claims of extreme synergy increases-often cited as up to "54-fold"-originate from a single in vitro and animal study that combined a CJC-1295 analog with GHRP-2, not Ipamorelin. No published data demonstrate a comparable multiplier for the CJC-1295 + Ipamorelin combination in humans. These numbers should not be extrapolated to set expectations for the stack.

"Safer than real HGH?"

It is frequently argued that the pulsatile GH release produced by secretagogues is more physiological-and therefore safer-than injecting exogenous HGH, because it does not shut down the pituitary axis. While this is mechanistically plausible, no clinical comparison data in humans exist to confirm that the side-effect profile is genuinely lower. This presumed safety advantage remains unproven, not established fact.

Does Ipamorelin make you hungry?

No. Unlike some other secretagogues such as GHRP-6, which strongly stimulate appetite, Ipamorelin has no documented significant hunger stimulation. It also has minimal impact on ghrelin itself, which distinguishes it from less selective ghrelin-receptor agonists.

How effective is CJC-1295 + Ipamorelin?

Clinical evidence for the individual substances shows meaningful increases in growth-hormone output-a frequently cited figure of approximately 7.5-fold greater GH pulsatility versus placebo is attributed to CJC-1295 in controlled studies, though the specific primary source for this figure has not been definitively identified-but no published randomized controlled trials exist for the specific CJC-1295 + Ipamorelin combination in healthy adults, leaving practical efficacy largely inferred from mechanism and individual-drug data.

The evidence base is mechanistically well-founded but clinically incomplete. Key findings include:

• CJC-1295 alone: Two placebo-controlled studies in healthy adults are frequently cited for prolonged GH and IGF-1 stimulation, including a ~7.5-fold increase in GH pulsatility compared to placebo, though the specific primary source for this figure has not been definitively identified.
• Ipamorelin alone: The first selective growth-hormone secretagogue, documented to produce rapid, short-duration GH peaks without significantly elevating cortisol, prolactin, or appetite.
• The combination: No published randomized controlled trials (RCTs) exist for the CJC-1295 + Ipamorelin stack in healthy adults, trained athletes, or anti-aging populations. Clinical studies have been conducted primarily in specific patient groups-adults with GH deficiency, postoperative gastrointestinal recovery, and HIV-related muscle wasting.
• Research volume: A systematic PubMed search yields approximately 12 studies related to these peptides, which is a notably thin evidence base.

The physiological benefits most commonly reported-improved recovery, increased bone density, cardiovascular support, enhanced libido, neuroprotection, and improved cognition-are largely derived from the general GH/IGF-1 elevation rather than from direct studies of body-composition changes with this specific combination.

Comparison with related substances

Dosage: what the studies show - and the course

Published dosing data is limited: CJC-1295 has been studied at doses producing sustained GH elevation for multiple days, while Ipamorelin produces a rapid peak around 0.67 hours post-injection-but no validated dosing protocol for the combination in healthy adults exists, making any specific regimen a matter of community convention rather than clinical consensus.

The information below reflects doses referenced in the available literature and community protocols. These are not medical recommendations-they are documented for harm-reduction purposes only.

Two critical points apply to all dosing: First, the commonly referenced 100-300 mcg ranges are community convention, not study-validated protocols for the specific combination. Second, the DAC variant must be treated as distinct from the non-DAC variant at all times-its multi-day half-life means dosing frequency and accumulation risks are fundamentally different.

Reconstitution & dose calculation

Both peptides are typically sold as lyophilized powder in vials and must be reconstituted with bacteriostatic water before subcutaneous injection; the concentration depends on the amount of solvent added, so accurate dose calculation requires knowing both the vial's peptide content and the reconstitution volume-not just the number on the label.

Basic reconstitution principles:

• Check the vial: Confirm the peptide amount (e.g., 5 mg) and whether the product is CJC-1295 with or without DAC. These are fundamentally different substances with different half-lives and safety profiles.
• Reconstitution volume determines concentration: Adding 2 mL of bacteriostatic water to a 5 mg vial yields a concentration of 2.5 mg/mL (2,500 mcg/mL). Adding 1 mL to the same vial yields 5 mg/mL (5,000 mcg/mL).
• Subcutaneous injection: Administered under the skin, typically in abdominal or thigh tissue. Accidental intravenous injection increases the risk of acute histamine reactions.
• Storage after reconstitution: Reconstituted peptides should be refrigerated; specific stability windows depend on the formulation.

Accidental intravenous injection has been linked to severe histamine reactions, including whole-body urticaria (hives). Proper subcutaneous technique and needle selection are essential harm-reduction measures.

Side effects and common mistakes

Reported side effects range from expected and transient reactions-facial flushing, water retention, and early headaches-to potentially dangerous histamine responses including whole-body hives requiring emergency care; the DAC variant carries an additional unresolved safety signal from a fatal cardiovascular event during clinical development, making substance identification and injection technique critical harm-reduction priorities.

Expected and transient side effects

• Facial flushing and redness: A short-lived sensation of warmth and visible redness in the face, typically resolving within ~30 minutes. This is specifically attributed to CJC-1295, not Ipamorelin, and is generally considered an expected reaction.
• Water retention: A known effect of elevated growth hormone. It occurs more frequently with the CJC-1295 DAC variant and can cause tingling or numbness in the hands when fluid retention compresses the median nerve (carpal-tunnel-like symptoms).
• Headaches: Reported in the first 2-4 weeks, particularly at higher doses, and often associated with dehydration.

Dangerous histamine reactions - stop immediately if worsening

Community reports include well-documented cases of severe histamine reactions, including whole-body urticaria (hives). In one documented case, administration of an EpiPen and an emergency-room visit were required. The risk increases with accidental intravenous injection or with progressive sensitization over weeks of use.

Red-flag warning: If injection-site reactions (red welts, wheals, or hives) worsen with each successive injection, stop immediately. Escalating reactions signal increasing sensitization that can progress to a systemic emergency.

Frequently asked practical questions

Can I just stop? If injections produce red spots or wheals that get progressively worse with each shot, stop immediately-this pattern indicates escalating sensitization, not a normal reaction to tolerate.

Does Ipamorelin make you hungry? No. Unlike GHRP-6 and some other secretagogues that strongly stimulate appetite, Ipamorelin has no documented significant hunger effect.

Is the stack safer than injecting real HGH? Mechanistically, the pulsatile release pattern is more physiological than continuous exogenous HGH exposure. However, no clinical comparison data in humans confirm that side effects are actually fewer. This safety advantage is theorized, not proven.

Common mistakes

• Not knowing which CJC-1295 variant you have: DAC and non-DAC are fundamentally different substances with different half-lives, safety signals, and dosing logic.
• Extrapolating the "54-fold synergy" to the stack: That figure comes from a GHRP-2 study, not an Ipamorelin study, and from animal/in vitro data-not human trials.
• Ignoring escalating injection-site reactions: Worsening wheals after each shot signal sensitization that can escalate to a systemic emergency.
• Assuming "research peptide" labeling means safety-tested: These substances are sold for research purposes and are not subject to pharmaceutical quality standards or human safety monitoring.
• Treating community dosing conventions as validated protocols: The widely shared dose ranges have no RCT backing for this specific combination.

Approval and legal status

Neither CJC-1295 nor Ipamorelin is approved by the FDA, EMA, or any other major regulatory body for any medical indication; both are classified as experimental, sold as "research peptides," listed on the WADA Prohibited List for competitive sports, and restricted under US compounding regulations-meaning all human use occurs off-label and without regulatory oversight.

Despite the lack of approvals, some modern clinics promote the CJC-1295 + Ipamorelin stack as a "leading-edge" alternative to older approved peptides such as Sermorelin. These promotional claims are not supported by independent head-to-head comparison data.